Latest News

European Commission approves linvoseltamab for the treatment of relapsed and refractory myeloma

On 23th April 2025, the European Commission has granted conditional marketing approval of linvoseltamab to treat adults with relapsed and refractory myeloma. Conditional approval means that linvoseltamab will be reassessed for safety and efficacy when the results of other, larger clinical trials become available. This approval is based on the favourable recommendation issued by the…

Read more

EMA CHMP gives positive opinion on linvoseltamab for relapsed/refractory myeloma patients

On 27th February 2025, the Committee for Medicinal Products for Human Use (CHMP) recommended the approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma. The CHMP is the European Medicines Agency’s committee responsible for opinions on all issues regarding medicinal products for human use. Based on these opinions, then the European Commission…

Read more

June 2026

MO
TU
WE
TH
FR
SA
SU
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
1
2
3
4
5
Events for 1st June
No Events
Events for 2nd June
No Events
Events for 3rd June
No Events
Events for 4th June
No Events
Events for 5th June
No Events
Events for 6th June
No Events
Events for 7th June
No Events
Events for 8th June
No Events
Events for 9th June
No Events
Events for 10th June
No Events
Events for 11th June
No Events
Events for 12th June
No Events
Events for 13th June
No Events
Events for 14th June
No Events
Events for 15th June
No Events
Events for 16th June
No Events
Events for 17th June
No Events
Events for 18th June
No Events
Events for 19th June
No Events
Events for 20th June
No Events
Events for 21st June
No Events
Events for 22nd June
No Events
Events for 23rd June
No Events
Events for 24th June
No Events
Events for 25th June
No Events
Events for 26th June
No Events
Events for 27th June
No Events
Events for 28th June
No Events
Events for 29th June
No Events
Events for 30th June
No Events